CRISPR Just Got Smaller and That’s a Big Deal
One of CRISPR’s biggest problems? It’s too bulky to deliver easily. Mammoth Biosciences just shrunk it down. Their new NanoCas is about a third the size of CRISPR-Cas9, making it way easier to use in gene therapy—think muscles, brain, and heart. The team is already eyeing brain diseases, and the tech could also be tweaked for epigenetic or base editing. This could be a huge leap for medicine.